The inhibitory effect of CUGBP1 on IFN-γ suggests that the pro- and anti-fibrotic molecular pair CUGBP1-IFN-γ can be a potential target to control HSC activation for the treatment of liver fibrosis. This evidence concerns the gene IFNG and Hepatic fibrosis.